Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 6/2016

01-12-2016 | Review Article

Current and Emerging Therapies for Itch Management in Psoriasis

Authors: Carolyn Stull, Shoshana Grossman, Gil Yosipovitch

Published in: American Journal of Clinical Dermatology | Issue 6/2016

Login to get access

Abstract

Pruritus is a common and significant symptom among patients with psoriasis. Pruritus is often present beyond the borders of psoriatic plaques, and frequently affects the scalp and genital regions. Psoriatic itch may be severe and can profoundly affect quality of life and sleep, even in the context of mild-to-moderate disease. These features often make the treatment of psoriatic pruritus challenging. However, there are a variety of effective topical and systemic treatment modalities available to address this symptom. While there remains a need for treatments that specifically target psoriatic itch, newly licensed therapies including secukinumab, ixekizumab and apremilast have been shown to rapidly and effectively mediate itch reduction.
Literature
1.
2.
Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143(5):969–73.CrossRefPubMed
3.
Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151(3):594–9.CrossRefPubMed
4.
Reich A, Hrehorow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90(3):257–63.CrossRefPubMed
5.
Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
6.
Kimball AB, Edson-Heredia E, Zhu B, Guo J, Maeda-Chubachi T, Shen W, et al. Understanding the relationship between pruritus severity and work productivity in patients with moderate-to-severe psoriasis: sleep problems are a mediating factor. J Drugs Dermatol. 2016;15(2):183–8.PubMed
7.
Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18(3):227–33.PubMed
8.
O’Neill JL, Chan YH, Rapp SR, Yosipovitch G. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. Acta Derm Venereol. 2011;91(5):537–40.CrossRefPubMed
9.
Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70(2):390–1.CrossRefPubMed
10.
Czarnecka-Operacz M, Polanska A, Klimanska M, Teresiak-Mikolajczak E, Molinska-Glura M, Adamski Z, et al. Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations. Postepy Dermatol Alergol. 2015;32(6):426–30.CrossRefPubMedPubMedCentral
11.
Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nikai E, et al. Psychometric properties of the itch numeric rating scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016. doi:10.​1111/​bjd.​14464.PubMed
12.
Stander S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) special interest group scoring itch in clinical trials. Acta Derm Venereol. 2013;93(5):509–14.CrossRefPubMed
13.
Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8.CrossRefPubMed
14.
Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.CrossRefPubMed
15.
Moynes DM, Vanner SJ, Lomax AE. Participation of interleukin 17A in neuroimmune interactions. Brain Behav Immun. 2014;41:1–9.CrossRefPubMed
16.
Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156(6):1272–7.CrossRefPubMed
17.
Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–30.CrossRefPubMed
18.
Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a ‘hot’ medicine is reignited. Expert Opin Pharmacother. 2010;11(8):1359–71.CrossRefPubMed
19.
Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1993;29(3):438–42.CrossRefPubMed
20.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–24.CrossRefPubMed
21.
Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 1999;79(2):118–21.CrossRefPubMed
22.
Stander S, Schurmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2(2):213–8.CrossRefPubMedPubMedCentral
23.
Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res. 2004;50(3):257–62.CrossRefPubMed
24.
Stander S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt. 2003;54(5):413–7.CrossRefPubMed
25.
Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63–8.CrossRefPubMed
26.
Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337–56.CrossRefPubMed
27.
Kircik L. Salicylic acid 6 % in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270–3.PubMed
28.
Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(4):399–410.CrossRefPubMed
29.
Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.PubMed
30.
Thirupathi A, Elango T, Subramanian S, Gnanaraj P. Methotrexate regulates th-1 response by suppressing caspase-1 and cytokines in psoriasis patients. Clin Chim Acta. 2016;30(453):164–9.CrossRef
31.
Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27–39.
32.
Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63(6):925–46 (quiz 947–8).
33.
Schewitz-Bowers LP, Lait PJ, Copland DA, Chen P, Wu W, Dhanda AD, et al. Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proc Natl Acad Sci. 2015;112(13):4080–5.CrossRefPubMedPubMedCentral
34.
Schopf RE, Hultsch T, Lotz J, Brautigam M. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A. J Eur Acad Dermatol Venereol. 1998;11(3):234–9.CrossRefPubMed
35.
Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, short-term ciclosporin (neoral(R)) therapy is effective in improving patients’ quality of life as assessed by skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol. 2011;38(5):465–72.CrossRefPubMed
36.
Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121–36.CrossRefPubMed
37.
Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2012;23(3):203–7.CrossRefPubMed
38.
Gottlieb A, Feng J, Harrison DJ, Globe D. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(4):580–6.CrossRefPubMed
39.
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–9.CrossRefPubMed
40.
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.CrossRefPubMed
41.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.CrossRefPubMed
42.
Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.CrossRefPubMed
43.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.CrossRefPubMed
44.
Kimball A, Nikai E, Zhu B, Carlier H, et al. Ixekizumab impact on itch severity compared to etanercept and placebo: results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis. J Invest Dermatol. 2015;135(Supplement 3):S19–S19.
45.
Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514–20.CrossRefPubMed
46.
Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–29.CrossRefPubMed
47.
Krueger J, Clark JD, Suarez-Farinas M, Fuentes-Duculan J, Cueto I, Wang CQ, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137(4):1079–90.CrossRefPubMed
48.
Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the itch severity score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015;26(2):121–3.CrossRefPubMed
49.
Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26(1):19–22.CrossRefPubMed
50.
Papp K, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral JAK1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–76.CrossRefPubMed
51.
Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase 2a study. Br J Dermatol. 2016;174(5):985–95.CrossRefPubMed
52.
Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci. 2016;17(3). doi:10.​3390/​ijms17030425.
53.
Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage. 2003;25(3):288–91.CrossRefPubMed
54.
Puzantian T. Mirtazapine, an antidepressant. Am J Health Syst Pharm. 1998;55(1):44–9.PubMed
55.
Stull C, Lavery MJ, Yosipovitch G. Advances in therapeutic strategies for the treatment of pruritus. Expert Opin Pharmacother. 2015;23:1–17.
56.
Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol. 1999;140(5):887–90.CrossRefPubMed
57.
Levin AA, Aleissa S, Dumont N, Martinez F, Donovan C, Au SC, et al. A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis. J Drugs Dermatol. 2014;13(8):922–6.PubMed
58.
Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, et al. Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy. Br J Dermatol. 2009;161(3):542–6.CrossRefPubMed
59.
Metadata
Title
Current and Emerging Therapies for Itch Management in Psoriasis
Authors
Carolyn Stull
Shoshana Grossman
Gil Yosipovitch
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 6/2016
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-016-0213-5

Other articles of this Issue 6/2016

American Journal of Clinical Dermatology 6/2016 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Review Article

Considerations for Systemic Treatment of Psoriasis in Obese Patients

Review Article

Primary and Secondary Chemoprevention of Malignant Melanoma

Review Article

Exercise-Induced Vasculitis: A Review with Illustrated Cases

Erratum

Erratum to: Shiitake Mushroom Dermatitis: A Review

Evidence-Based Review

Phototherapy for Pityriasis Lichenoides in the Pediatric Population: A Review of the Published Literature